ArticleIDCases2026
Grave's disease as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected child on highly active antiretroviral therapy: A case report.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune reconstitution inflammatory syndrome (IRIS) can unmask autoimmune disease after antiretroviral therapy (ART), and Graves' disease has been reported as a late autoimmune manifestation, though pediatric cases are exceptionally rare. Case presentation: A 9-year-old Ethiopian boy with vertically acquired HIV, diagnosed at age 6 during an acute illness, had presented at that time with profound immunosuppression (CD4 23 cells/mm³, HIV RNA ∼150,000 copies/mL) and was started on combination ART. He achieved sustained virologic suppression and marked immune recovery (CD4 >1800 cells/mm³). Thirty-three months after ART initiation he developed a six-month history of weight loss, palpitations, increased appetite, night sweats and progressive bilateral proptosis. Examination showed tachycardia, lid retraction, lid lag and a diffusely enlarged, soft, non-tender goitre. Laboratory testing revealed suppressed TSH and elevated free T4; thyroid ultrasound demonstrated a diffusely enlarged, hypervascular gland. Thyroid autoantibodies were not available. A clinical diagnosis of Graves' disease in the context of IRIS was made. Management and outcome: ART was continued. He was treated with carbimazole and propranolol with close endocrine and infectious-disease follow-up. Symptoms resolved, heart rate normalized and thyroid function tests returned to the euthyroid range, allowing down-titration of carbimazole to a maintenance dose. Conclusion: This case illustrates that Graves' hyperthyroidism may present as a late IRIS manifestation in children with profound immune recovery after ART. Early recognition, standard antithyroid therapy and continuation of ART can achieve good outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.